Skip to main content

Table 1 List of approved drugs targeting CTLA-4 and PD-1 (current as May 2019)

From: Combination of CTLA-4 and PD-1 blockers for treatment of cancer

Drug Brand name Indication
CTLA-4 blockers
 Ipilimumab Yervoy As monotherapy for metastatic melanoma and surgically resectable ‘high-risk’ melanoma (adjuvant setting)
PD-1 blockers
 Nivolumab Opdivo Metastatic melanoma, metastatic non-small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), classical Hodgkin’s lymphoma, head and neck squamous cell carcinoma (HNSCC), metastatic urothelial carcinoma, hepatocellular carcinoma (HCC), colorectal cancer with MSI-H and MMR aberrations
 Pembrolizumab Keytruda Metastatic melanoma, surgically resectable ‘high-risk melanoma (adjuvant setting), metastatic NSCLC, classical Hodgkin’s lymphoma, primary mediastinal B-cell lymphoma (PMBCL), HNSCC, gastric cancer, solid tumors with MSI-H and MMR aberrations, metastatic urothelial carcinoma, Merkel cell carcinoma, renal cell carcinoma, cervical cancer, hepatocellular carcinoma,
 Cemiplimab Libtayo Metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation
PD-L1 blockers
 Atezolizumab Tecentriq Metastatic urothelial carcinoma, metastatic NSCLC (monotherapy and in combination with chemotherapy), metastatic SCLC (in combination with chemotherapy) and metastatic triple negative breast cancer (in combination with paclitaxel)
 Avelumab Bevencio Merkel cell carcinoma, metastatic urothelial carcinoma
 Durvalumab Imfinzi Metastatic urothelial carcinoma, unresectable stage III NSCLC
Combination of CTLA-4 and PD-1 blockers
 Ipilimumab plus nivolumab Yervoy plus Opdivo Metastatic melanoma, metastatic renal cell carcinoma, colorectal cancer with MSI-H and MMR aberrations